Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
Arcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckonsArmed with a positive mid-stage trial readout in lung cancer, Arcus Biosciences will expand a phase 3 programme Share XArcus preps more phase 3 trials for TIGIT antibody, as Gilead opt-in beckonshttps://pharmaphorum.com/news/arcus-preps-more-phase-3-trials-for-tigit-antibody-as-gilead-opt-in-beckons/
AZ, HutchMed’s savolitinib gets 1st approval in China for NSCLCAstraZeneca and HutchMed have claimed their first approval – in China – for cMET inhibitor savolitinib as a Share XAZ, HutchMed’s savolitinib gets 1st approval in China for NSCLChttps://pharmaphorum.com/news/az-hutchmeds-savolitinib-gets-1st-approval-in-china-for-nsclc/
Heat Bio’s shares ignite on Opdivo combination data in NSCLCThe pairing of Heat Biologics’ lead drug HS-110 with Bristol-Myers Squibb’s blockbuster checkpoint inhibitor Opdivo has boosted survival Share XHeat Bio’s shares ignite on Opdivo combination data in NSCLChttps://pharmaphorum.com/news/heat-bios-shares-ignite-on-opdivo-combination-data-in-nsclc/
Roche nabs breakthrough tag for TIGIT cancer immunotherapyRoche’s closely-watched combination of two checkpoint inhibitors – TIGIT-targeting tiragolumab and PD-L1 drug Tecentriq – has claimed breakthrough Share XRoche nabs breakthrough tag for TIGIT cancer immunotherapyhttps://pharmaphorum.com/news/roche-nabs-breakthrough-tag-for-tigit-cancer-immunotherapy/
J&J files lung cancer bispecific amivantamab for FDA approvalJohnson & Johnson has filed its bispecific antibody amivantamab to the FDA, hoping to muscle into the big Share XJ&J files lung cancer bispecific amivantamab for FDA approvalhttps://pharmaphorum.com/news/jj-files-lung-cancer-bispecific-amivantamab-for-fda-approval/
Genprex cancer gene therapy paired with AZ, Merck lung cancer drugsAn experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Share XGenprex cancer gene therapy paired with AZ, Merck lung cancer drugshttps://pharmaphorum.com/news/genprex-cancer-gene-therapy-paired-with-az-merck-lung-cancer-drugs/
FDA sets Feb decision date for Libtayo lung cancer challenge to KeytrudaThe FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell Share XFDA sets Feb decision date for Libtayo lung cancer challenge to Keytrudahttps://pharmaphorum.com/news/fda-sets-feb-decision-date-for-libtayos-lung-cancer-challenge-to-keytruda/
FDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerThe FDA has granted a fast review for AstraZeneca’s Tagrisso oncology drug in certain patients with early-stage lung Share XFDA grants fast review for AstraZeneca’s Tagrisso in early-stage lung cancerhttps://pharmaphorum.com/news/fda-grants-fast-review-for-astrazenecas-tagrisso-in-early-stage-lung-cancer/
